Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Rating of “Hold” from Brokerages

Shattuck Labs, Inc. (NASDAQ:STTK) has been given an average recommendation of “Hold” by the seven analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $6.20.

Several equities research analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a research note on Thursday, January 22nd. HC Wainwright upgraded Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Monday, December 1st. Piper Sandler initiated coverage on Shattuck Labs in a research note on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price target for the company. Finally, Citigroup raised their price objective on Shattuck Labs from $2.00 to $4.00 and gave the company a “neutral” rating in a research note on Tuesday, January 6th.

Shattuck Labs Price Performance

Shares of Shattuck Labs stock opened at $3.85 on Thursday. The firm has a market cap of $243.63 million, a price-to-earnings ratio of -3.77 and a beta of 1.52. The stock has a 50-day simple moving average of $3.63 and a 200-day simple moving average of $2.33. Shattuck Labs has a 52-week low of $0.69 and a 52-week high of $4.89.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. The business had revenue of $1.00 million for the quarter. As a group, equities research analysts predict that Shattuck Labs will post -1.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of STTK. Aberdeen Group plc grew its position in shares of Shattuck Labs by 462.1% in the fourth quarter. Aberdeen Group plc now owns 531,177 shares of the company’s stock valued at $1,939,000 after purchasing an additional 436,673 shares during the last quarter. Mallini Complete Financial Planning LLC bought a new stake in Shattuck Labs during the 4th quarter valued at approximately $83,000. Keel Point LLC acquired a new stake in Shattuck Labs in the 3rd quarter valued at approximately $110,000. Bank of America Corp DE increased its position in Shattuck Labs by 2,968.2% in the 3rd quarter. Bank of America Corp DE now owns 1,131,888 shares of the company’s stock worth $2,705,000 after buying an additional 1,094,997 shares during the period. Finally, Virtu Financial LLC bought a new position in Shattuck Labs in the 3rd quarter worth approximately $38,000. 58.74% of the stock is currently owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.